CYGX

[Mags]

Captn'

Captn'

Any more news on CYGX? (yes, I bought some too - however, got in pretty late, so I am not in the money as we speak)

 

[HoopsGuru]

here's an article from yahoo finance this morning.


HOUSTON--(BUSINESS WIRE)--Jan. 12, 2005--CytoGenix Inc. (OTCBB:CYGX - News) announced that Dr. Yin Chen, vice president of Research and Development has been invited to present the results of experiments leading to identification of novel antibacterial agents at the Keystone Symposia Meeting the Challenges of Drug Discovery conference to be held Jan. 15 through 20, 2005, in Vancouver, British Columbia.
Dr. Chen's presentation describes the discovery of new antibacterial targets and agents that defeat bacteria antibiotic resistance mechanisms. It is titled "A novel genomic approach identifies bacterial DNA-dependent RNA polymerase as a target of an antibacterial oligodeoxynucleotide, RBL1."

Since 1972, Keystone Symposia, www.keystonesymposia.org, a non-profit institution, serves as a catalyst for the advancement of biomedical and life sciences by connecting scientists within and across disciplines at conferences and workshops held at venues that create an environment conducive to information exchange, generation of new ideas, and acceleration of applications that benefit society.

Dr. Malcolm Skolnick, CytoGenix president and CEO, commented, "One of our company's most important goals is demonstrating the quality of our work to our scientific peers. We are pleased that Dr. Chen is presenting the results of our latest research at this prestigious venue to portray the scientific merit and potential medical benefit of these results."

CytoGenix Inc. is a Houston-based biopharmaceutical company that develops and markets innovative products and services based on its proprietary ssDNA expression technology. CytoGenix currently has one issued U.S. patent and over 48 international or U.S. pending patent applications claiming methods and materials in connection with this platform technology.

 

[Captain Crunch]

Welcome aboard Mags. The NR HoopsGuru posted is the lateset and should give the company some exposure. Supposedly it is a pretty big deal to get asked to go to this conference.

Remember to not get discouraged by the daily price fluctuations and look at the big picture. One of the posters on the forum that I listed above has an uncanny abiltiy to predict upward price moves. I'm pretty sure he knows someone associtated with the company, but for obvious reasons, doesn't go into any detail why he thinks the price is heading north. He is thinking we should be at a $1.25 by Valentines day and $15 by the middle of this year. Take that for what its worth, but he is not any kind a pump and dump type of person. For him to say that, I'm thinking we might be instore for some nice NR's in the near future, but it is only a guess on his part as no one really knows what the price will be. They have a lot of things going on, and if one of these things hits, his prediction will probably be low IMO.

I will start to post the NR's on a regular basis here if HG doesn't beat me to it, but it looks like he has this one on his radar screen.

Good Luck

 

[HoopsGuru]

CytoGenix Conducts Pre-IND FDA Conference for CY301 Herpes Cream
Tuesday January 25, 10:00 am ET


HOUSTON--(BUSINESS WIRE)--Jan. 25, 2005--CytoGenix Inc. (OTCBB:CYGX - News) announced that on Jan. 18, 2005, company representatives participated in a teleconference with members of the Food and Drug Administration's Center for Biologics Evaluation and Research (CBER) concerning the company's CY301 anti-herpes topical agent Investigational New Drug application (IND).
In preparation for the IND filing later this year, experts from the CBER Division of Cellular and Gene Therapies provided comments, guidance and clarification about the Agency's pre-clinical requirements for CY301 anti-herpes topical treatment. The FDA team included specialists in toxicology, pharmacology, virology and clinical research.

Dr. Malcolm Skolnick, CytoGenix president and CEO, commented, "This event is a very important milestone in the history of the company. It is our first conference with the FDA about marketing a product that uses the company's proprietary single stranded DNA expression technology. The interchange was useful, and the FDA officials were very helpful in reviewing the requirements for filing an IND for the CY301 anti-herpes treatment. We will comply with the letter and spirit of the regulations, as we gain valuable experience while establishing credibility with the group that will review many of our new product submissions in the future."

CytoGenix Inc. is a Houston-based biopharmaceutical company that develops and markets innovative products and services based on its proprietary ssDNA expression technology. The company has developed a breakthrough synthetic process for large-scale production of high purity FDA at a fraction of the cost of traditional fermentation methods. CytoGenix currently has one issued US patent and over 48 international or US pending patent applications claiming methods and materials in connection with this platform technology.

 

[Mags]

Positive News, big price drop?

Positive News, big price drop?

I don't understand... :shrug:

 

[HoopsGuru]

i believe it means they need to do a little more work before they progress with their testing/patents in india which means that short term investors are nervous and sold but i wouldn't worry if you are a long term holder. captain crunch can probably elaborate better. i've only followed this stock for a short time.

 

[Captain Crunch]

I think Hoops nailed it. I think there were a lot of investors who thought herpes clinicals were starting this quarter, and by the way todays NR reads, it is going to be a little later in the year. I think the short term "traders" bailed today and that is why we saw the price go down. Classic sell on the news IMO. I still think the long term prospects for this one are solid and still have that hunch that there is some good news coming in the near term. Like I stated in a previous post, watching the daily price swings in penny stocks will drive you crazy. I am still holding every share I have and have no intentions of selling anytime soon. I just wish I had some free cash to buy some more.

Good Luck

 

[zsbob9]

It is it a good time to get in this stock (currently .63); would you wait until it drops into the .55 range. Thanks in advance.

 

[TJBELL]

Captain: Why are all the big wheels selling??????

http://finance.yahoo.com/q/it?s=CYGX.OB

 

[Captain Crunch]

TJ, I saw that the other day. As I said in the other thread, alot of restricted shares became unrestricted and these people who bought at $.03 are probably selling and realizing some nice profits. The big wheels are the ones that purchased the shares on OCT. 25. Notice their titles below their name. I have never heard of those people who filed to sell those shares. From what I understand, they have 90 days to sell once they file their intent to sell. Whether they have to sell or not, I am not sure, but I think if you have a large number (not sure how that part works relative to the number of outstanding shares) of shares and are going to buy or sell, you have to file some form and get put on these lists so the public can see what you are doing. I am sure it has to do with insider trading rules or something similar.

zsbob9, I have bought shares from $.20 up to the mid $1.00 range over a period of five years. I would have to say that anything in the area it has been trading at the last few days would be a good entry point based on what I think the potetial is of this company. I obviously have no idea where the short term price swings are going to go, so you are going to have to decide that for yourself. I don't work next to a computer during the day, so I am not able to watch the price minute by minute and try and anticipate where a good entry point would be. I think you know how I feel about this stock by the tone of my posts, and if you do a little DD yourself and use a little common sense, I think you could see how if they get one of these products to market, these sub dollar prices will be a thing of the past. I guess that is where the gamble comes in, but look where we are at. LOL

Good Luck

 

[TJBELL]

Part 1:





VectorVest Stock Analysis of Cytogenix Inc as of 2/24/2005


Thank you for requesting an analysis of Cytogenix Inc from VectorVest. The ticker symbol for Cytogenix Inc is CYGX. CYGX is traded on the Bulletin Board - (B)

Analysis Summary
CYGX is overvalued compared to its Price of $0.62 per share, has somewhat below average safety, and is currently rated a Hold.

In-Depth Analysis
Business: Cytogenix Inc, (CYGX) is a biotechnology research and development company focusing on the intracellular expression of single stranded DNA. The Company holds exclusive rights to technology that produces single stranded DNA in bacteria, plants, and animals. CytoGenix seeks to incorporate this procedure into the antisense gene therapy market.

Price: CYGX closed on 2/24/2005 at $0.62 per share

Value: Value is a measure of a stock's current worth. CYGX has a current Value of $0.06 per share. Therefore, it is overvalued compared to its Price of $0.62 per share. Value is computed from forecasted earnings per share, forecasted earnings growth, profitability, interest, and inflation rates. Value increases when earnings, earnings growth rate and profitability increase, and when interest and inflation rates decrease. VectorVest advocates the purchase of undervalued stocks. At some point in time, a stock's Price and Value always will converge.

RV (Relative Value): RV is an indicator of long-term price appreciation potential. CYGX has an RV of 0.17, which is very poor on a scale of 0.00 to 2.00. This indicator is far superior to a simple comparison of Price and Value because it is computed from an analysis of projected price appreciation three years out, AAA Corporate Bond Rates, and risk. RV solves the riddle of whether it is preferable to buy High growth, High P/E stocks, or Low growth, Low P/E stocks. VectorVest favors the purchase of stocks with RV ratings above 1.00.

RS (Relative Safety): RS is an indicator of risk. CYGX has an RS rating of 0.79, which is poor on a scale of 0.00 to 2.00. RS is computed from an analysis of the consistency and predictability of a company's financial performance, debt to equity ratio, sales volume, business longevity, price volatility and other factors. A stock with an RS rating greater than 1.00 is safer and more predictable than the average stock in the VectorVest database. VectorVest favors the purchase of stocks of companies with consistent, predictable financial performance.

RT (Relative Timing): RT is a fast, smart, accurate indicator of a stock's price trend. CYGX has a Relative Timing rating of 1.06, which is fair on a scale of 0.00 to 2.00. RT is computed from an analysis of the direction, magnitude, and dynamics of a stock's price movements over one day, one week, one quarter and one year time periods. Once a stock's price has established a strong trend, it is expected to continue in that trend for the short-term. If a trend dissipates, RT will gravitate toward 1.00. RT will explode from bottoms, dive from tops, and reflect changes in price momentum. VectorVest favors the purchase of stocks with RT ratings above 1.00.

VST (VST-Vector): VST is the master indicator for ranking every stock in the VectorVest database. CYGX has a VST rating of 0.80, which is poor on a scale of 0.00 to 2.00. VST is computed from the square root of a weighted sum of the squares of RV, RS, and RT. Stocks with the highest VST ratings have the best combinations of Value, Safety and Timing. These are the stocks to own for above average, long-term capital appreciation. VectorVest advocates the purchase of safe, undervalued stocks rising in price.

CI (Comfort Index): CI is an indicator which reflects a stock's ability to resist severe and/or lengthy price declines. CYGX has a CI rating of 1.49, which is excellent on a scale of 0.00 to 2.00. CI is quite different from RS in that it is based solely upon a stock's long-term price history. VectorVest advocates the purchase of high CI stocks.

GRT (Earnings Growth Rate): GRT reflects a company's one to three year forecasted earnings growth rate in percent per year. CYGX has a forecasted Earnings Growth Rate of 2.00%, which VectorVest considers to be poor. GRT is computed from historical, current and forecasted earnings data. It is updated each week for every stock in the VectorVest database. GRT often foretells a stock's future price trend. If a stock's GRT trend is upward, the stock's price will likely rise. If GRT is trending downward, the stock's Price will probably fall. VectorVest favors the purchase of stocks whose GRT is rising and is greater than the sum of current inflation and interest rates, (8.66%).

 

[TJBELL]

Part: 2



Recommendation (REC): VectorVest gives a Buy, Sell, Hold recommendation on every stock, every day. CYGX has a Hold recommendation. REC reflects the cumulative effect of all the VectorVest parameters working together. These parameters are designed to help investors buy safe, undervalued stocks rising in price. They also help investors avoid or sell risky, overvalued stocks falling in price. VectorVest recommends that investors buy high VST-Vector, Buy-rated stocks in rising markets.

Stop (Stop-Price): Stop is an indicator of when to sell a long position or cover a short position. CYGX has a Stop of $0.60 per share. This is $0.02 below CYGX's current closing Price. A stock's Stop is computed from a 13 week moving average of its closing prices, and is fine-tuned according to the stock's fundamentals. High RV, high RS stocks have lower Stops, and low RV, low RS stocks have higher Stops. In the VectorVest system, a stock gets a 'B' or 'H' recommendation if its Price is above its Stop and an 'S' recommendation if its Price is below its Stop.

EPS (Earnings per Share): EPS stands for leading 12 months Earnings Per Share. CYGX has a forecasted EPS of $-0.02 per share. VectorVest determines this forecast from a combination of recent earnings performance and traditional fiscal and/or calendar year earnings forecasts.

P/E (Price to Earnings Ratio): P/E is a popular measure of stock valuation which shows the dollars required to buy one dollar of earnings. CYGX has a P/E of -31.00. This ratio may be deemed to be high or low depending upon your frame of reference. The average P/E of all the stocks in the VectorVest database is 31.15. P/E is computed daily using the formula: P/E = Price/EPS.

EY (Earnings Yield): EY reflects earnings per share as a percent of Price. EY is related to P/E via the formula, EY = 100 / (P/E), and may be used in place of P/E as a measure of valuation. EY has the advantages that it is always determinate and can reflect negative earnings. CYGX has an EY of -3.23 percent. This is below the current average of 3.21% for all the stocks in the VectorVest database. EY equals 100 x (EPS/Price).

GPE (Growth to P/E Ratio): GPE is another popular measure of stock valuation. It compares earnings growth rate to P/E ratio. CYGX has a GPE rating of -0.06. High growth stocks are believed to be able to justify high P/E ratios. A stock is commonly considered to be undervalued when GPE is greater than 1.00 and overvalued when GPE is below 1.00. Unfortunately, this rule of thumb does not take into account the effect of interest rates on P/E ratios. The operative GPE ratio of 1.00 is valid when and only when interest rates equal 10%. With long-term interest rates currently at 5.36%, the operative GPE ratio is 0.29. Therefore, CYGX may be considered to be overvalued.

DIV (Dividend): VectorVest reports annual, regular, cash dividends as indicated by the most recent payments. Special distributions, one-time payments, stock dividends, etc., are not generally included in DIV. CYGX does not pay a dividend.

DY (Dividend Yield): DY reflects earnings per share as a percent of Price. CYGX does not pay a dividend, so it does not have a Dividend Yield rating. . DY equals 100 x (DIV/Price). It is useful to compare DY with EY. If DY is not significantly lower than EY, the dividend payment may be in jeopardy.

DS (Dividend Safety): DS is an indicator of the assurance that regular cash dividends will be declared and paid at current or at higher rates for the foreseeable future. CYGX does not pay a dividend, so it does not have a Dividend Safety rating . Stocks with DS values above 75 typically have RS values well above 1.00 and EY levels that are much higher than DY.


DG (Dividend Growth Rate): Dividend Growth is a subtle yet important indicator of a company's financial performance. It also provides some insight into the board's outlook on the company's ability to increase earnings. CYGX does not pay a dividend, so it does not have a Dividend Growth rating .

YSG (YSG-Vector): YSG is an indicator which combines DIV, DY and DG into a single value, and allows direct comparison of all dividend-paying stocks in the database. CYGX does not pay a dividend, so it does not have a YSG rating . Stocks with the highest YSG values have the best combinations of Dividend Yield, Safety and Growth. These are the stocks to buy for above average current income and long-term growth.

Open: CYGX opened trading at a price of $0.68 per share on 2/24/2005.

High: CYGX traded at a High price of $0.68 per share on 2/24/2005.

Low: CYGX traded at a Low price of $0.60 per share on 2/24/2005

Close: CYGX closed trading at price $0.62 per share on 2/24/2005. (Close is also called Price in the VectorVest system)

Range: Range reflects the difference between the High and Low prices for the day. CYGX traded with a range of $0.08 per share on 2/24/2005.

$Change: CYGX closed down 0.06 from the prior day's closing Price.

%PRC: CYGX's Price changed -8.82% from the prior day's closing price.

Volume: CYGX traded 233,300 shares on 2/24/2005.

AvgVol: AvgVol is the 50 day moving average of daily volume as computed by VectorVest. CYGX has an AvgVol of 412,500 shares traded per day.

%Vol: %Vol reflects the percent change in today's trading volume as compared to the AvgVol. %Vol equals 100 x (Volume/AvgVol). CYGX had a %Vol of -43.44% on 2/24/2005

Sales: CYGX has annual sales of $

Sales Growth: Sales Growth is the Sales Growth Rate in percent over the last 12 months. CYGX has a Sales Growth of 15.00% per year. This is very good. Sales Growth is updated each week for every stock. It is often useful to compare Sales Growth to Earnings Growth to gain an insight into a company's operations.

Sales Per Share (SPS): CYGX has annual sales of $0.00 per share. SPS can be used as a measure of valuation when comparing stocks within an Industry Group.

Price to Sales Ratio (P/S): CYGX has a P/S of 0.00. This ratio is also used as a measure of valuation. Here, too, it is useful when comparing stocks within an Industry Group.

Shares: CYGX has 100,000,000 shares of stock outstanding.

Market Capitalization: CYGX has a Market Capitalization of $62,000,000. Market Capitalization is calculated by multiplying price times shares outstanding.

Industry Group: CYGX has been assigned to the Drug (Biomedical\Genetic) Industry Group. VectorVest classifies stocks into over 200 Industry Groups and 40 Business Sectors.

Business Sector: CYGX has been assigned to the Drug Business Sector. VectorVest classifies stocks into over 200 Industry Groups and 40 Business Sectors.

The basic strategy of VectorVest is to buy Low risk, High reward stocks. We suggest that Prudent investors buy enough High Relative Value, High Relative Safety stocks to keep the overall RV and RS ratings of their portfolios above 1.00. As you do this, you'll find that your risk will go down and your investment performance will improve.

 

[Captain Crunch]

Interesting reading TJ. I would guess that a lot of BB stocks would not fair very well with Vectorvest considering most of them don't have much money, haven't made much money, and haven't paid out any dividends. I guess we all knew this from the beginning with CYGX though.

A poster on the IHUB board posted the other day that they had inquired when any NR's could be expected. They (CYGX) stated that they hoped to be releasing the results of SEVERAL studies by the middle of March. Lets all hope they are positive in nature.

Good Luck

 

[TJBELL]

had inquired when any NR's could be expected.

Good Luck

Captain: What's an NR??

Just thought I would pass that info along. Keep us posted if you hear anything!!!!!

Thanks Bro!!! Good Luck!!! :thumb:

 

[Captain Crunch]

News Release

Some of these posters who I "think" have some sort of inside connection have been very quiet lately and haven't been posting much. It might be the "quiet before the storm." One of them made a PPS prediction for Valentines day, then came back a few days later and changed his time line to mid March, which coincides with what the rep from the company stated. We shall see, but can't help but think they will be on the postive side. IMO I know Hoops Guru has CYGX on his radar screen and has been good about posting updates when they come out. If I hear anything relevant on the IHUB board that looks to be factual, I will post it here.

Good Luck

 

[TJBELL]

Thanks Captain!!!

Hey, when you look up CYGX on Yahoo, you have to type in CYGX.OB

(What does the OB stand for??)

Thanks!

 

[Captain Crunch]

I'm not sure exactly. I think the exchange that it is traded on is the OTCBB, which is Over The Counter Bulletin Board. Maybe the OB is an abbreviatioin of that. There are certain requirements that must be met before they can trade on the NASDAQ, which will be the next step up, hopefully.

 

[Mags]

Hey Captain!

Hey Captain!

Knock on wood...

But look at CYGX go today.. up 0.22 as I type...

Hear anything that is going on to drive this big bump???? :clap:

 

[Mags]

Sorry guys, Yahoo mistake

Sorry guys, Yahoo mistake

I was watching this on yahoo - it showed it at 0.89 at one point today - but when I went back, it was obvious that Yahoo clearly made a mistake.... :cursin:

 

[Master Capper]

any suggestions on what firms to buy this stock through? I have used Sharebuilder for a few years but they are telling me that I cannot purchase this stock with a lump sum